Article Details

Rationale to conduct trial of Tozorakimab is not adequate: CDSCO tells AstraZeneca

Retrieved on: 2022-12-11 13:35:08

Tags for this article:

Click the tags to see associated articles and topics

Rationale to conduct trial of Tozorakimab is not adequate: CDSCO tells AstraZeneca. View article details on hiswai:

Excerpt

... Drug Standard Control Organization (CDSCO) has directed the drug maker AstraZeneca to submit proof of concept data for the proposed indication ...

Article found on: medicaldialogues.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up